Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Vaccines × Clear all
NCT06435351 2026-04-01

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Recruiting
16 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡